Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Biotech
Health
STAT+
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

Green shoots emerge in the frigid biotech IPO market

  • Damian Garde

By Damian Garde May 4, 2017

Reprints
New growth
Mark Kolbe/Getty Images

After a dismal first quarter for biotechs with Wall Street aspirations, a pair of small drug developers pulled off successful IPOs, suggesting 2017 may provide a warmer climate for an industry on the mend.

Two companies — BioHaven Pharmaceuticals and UroGen Pharma — successfully went public on Thursday, marking the fourth and fifth biotech IPOs of the second quarter. That tops the first quarter’s entire tally, according to Renaissance Capital, suggesting biotech is on the rebound after a four-year IPO nadir.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Tags

Medical device companies now need to prove to FDA…
Medical device companies now need to prove to FDA they’re protected against cyberattacks
Newly available test strips can detect lethal ‘tranq’ in…
Newly available test strips can detect lethal ‘tranq’ in drug supply
Why fentanyl is deadlier than heroin, in a single…
Why fentanyl is deadlier than heroin, in a single photo
New research may give geneticists a long-sought tool: a…
New research may give geneticists a long-sought tool: a targeted protein delivery device
British Columbia to bar Americans from buying Ozempic over…
British Columbia to bar Americans from buying Ozempic over supply concerns
Pharmalittle: WHO may add obesity drugs to essential medicines…
Pharmalittle: WHO may add obesity drugs to essential medicines list; monkey shortage may delay drug development

Recommended Stories